Moderna SARS-CoV-2 vaccine highly effective against alpha and beta variants

By | July 16, 2021
The Moderna SARS-CoV-2 vaccine was widely distributed and had a reported efficacy in clinical trials of 94.1% against the wildtype SARS-CoV-2 following the second dose administration. Therefore, Chemaitelly et al. used this as an opportunity to measure the vaccine’s efficacy against these variants as reported in a recent Nature Medicine paper, finding that the vaccine has good efficacy in all aspects.